A combined analysis of the NSABPB-31 and NCCTGN9831 studies revealed that trastuzumab combined with chemotherapy lowered the recurrence risk and mortality in HER2-positive breast cancer patients by 52% and 33% respectively (33, 89). Here, ERBB2 is linked to breast cancer.